Are Ecstasy Induced Serotonergic Alterations Overestimated For The Majority Of Users?

MDMA (±3,4-methylenedioxymethamphetamine), the principal active ingredient in ecstasy tablets, is widely used recreationally and has also attracted interest as a potential therapeutic agent. At the molecular level MDMA strongly affects serotonergic neurotransmission: it increases synaptic serotonin and its metabolite levels, alters reuptake mechanisms and influences related hormonal systems. Neuroimaging studies using PET and SPECT have frequently reported large reductions in cortical serotonin transporter (SERT) binding in people who use ecstasy, with reported group differences in the order of 40–70% compared with matched controls, and animal studies show similar SERT declines after chronic MDMA exposure. Szigeti and colleagues note a key uncertainty underlying this literature: whether participants enrolled in SERT imaging studies are representative of the broader population of recreational ecstasy users. The paper therefore aims to compare the ecstasy use patterns of participants in SERT imaging studies with data from the Global Drug Survey (GDS), a large international, self‑selected survey of drug use. In addition, the authors collate quantitative pill‑testing data from three drug‑checking services to characterise variability in MDMA content per pill and to assess whether pill strength could explain any differences in exposure between imaging samples and the wider user population.

The study combined three data sources and a literature search. First, the authors used GDS 2015, an anonymous, multilingual, web‑based survey run in November–December 2014. From 93,729 total completions they selected 11,168 respondents who reported at least one occasion of ecstasy pill use in the previous year. GDS provided self‑reported Usual Amount (pills per session) and Use Frequency (sessions per month, recorded categorically). Because GDS records past‑year use only, respondents who had used ecstasy more than a year previously were treated as non‑users for this analysis. Second, to identify SERT imaging studies the team searched PubMed and Google Scholar in February 2017 using terms related to MDMA, ecstasy, PET, SPECT and SERT. Inclusion required novel SERT data comparing ecstasy users with matched controls and sufficient reporting of participants' drug histories. From 292 retrieved publications, after abstract screening and exclusion of re‑analyses or studies with insufficient history data, 10 SERT imaging studies met these criteria and were included in the dose comparison. Third, quantitative pill testing data were obtained from three drug‑checking services (DIMS in the Netherlands, Energy Control in Spain and DIZ in Switzerland). These laboratories use analytical methods such as HPLC, GC‑MS and LC‑MS to quantify MDMA content in pills submitted as ecstasy; the authors used these data to characterise year‑to‑year variation in mean MDMA content and its standard deviation. To compare doses across data sources the investigators derived two composite measures. Dose Intensity (pills/year) was calculated as the product of mean Usual Amount (pills/session) and mean Use Frequency (sessions/month) with appropriate scaling to yield an annual estimate. An Intensity ratio was defined as Dose Intensity of a given SERT imaging group divided by the Dose Intensity of the GDS sample. Because GDS recorded Use Frequency categorically, the categories were converted to numeric monthly values by taking midpoints (for example, ‘once a month’ = 1 session/month; ‘1 or 2 times per week’ = 6.5 sessions/month). The authors note that many SERT imaging studies reported Lifetime Exposure and Time of Use, but Lifetime Exposure was not available in the GDS dataset, so the principal comparisons focused on current Usual Amount, Use Frequency and derived Dose Intensity.

In the GDS 2015 sample of recent ecstasy pill users (n = 11,168), the mean Usual Amount was 1.5 pills per session and the mean Use Frequency was 0.67 sessions per month, yielding an estimated Dose Intensity of 12.2 pills per year. Median values were lower: 1 pill per session and 0.5 sessions per month, with a median Dose Intensity of 6 pills per year (half the mean), indicating that the mean is pulled upward by heavier users. Across the 10 included SERT imaging studies, participants reported a higher mean Usual Amount (2.7 pills/session) and a substantially higher mean Use Frequency (2.6 sessions/month), giving an estimated Dose Intensity of 87.3 pills per year. On average, the imaging participants’ Usual Amount and Use Frequency correspond to the top 5–10% of the GDS sample, and the imaging groups’ estimated Dose Intensity is 720% higher than that of the GDS users. The authors emphasise that this Dose Intensity discrepancy is primarily driven by higher Use Frequency among imaging participants; median dosing for the imaging groups was rarely reported, limiting comparison by medians. Only two user subgroups among all reviewed imaging participants had a Dose Intensity equal to or lower than the GDS sample, and for those two groups reported SERT binding did not differ statistically from matched controls. This observation is presented alongside the consistent dose‑response relationship reported in the SERT literature, whereby greater MDMA exposure is associated with larger SERT reductions. Regarding pill strength, data from the three drug‑checking services showed a relatively stable mean MDMA content of around 90 mg per pill until 2009 and a subsequent increase thereafter. Energy Control reported a 35% increase in mean MDMA content up to 2015, while DIMS and DIZ recorded increases of about 70% and 80% respectively. The authors argue that the 35–80% rise in pill MDMA content is insufficient to account for the 720% difference in annual pill consumption between imaging samples and the GDS sample. Using the DIMS data as a conservative ‘worst case’ example, they estimate annual MDMA exposure for imaging participants at 8.5 g (96.6 pills × 87.1 mg/pill) versus 1.6 g for the GDS sample (10.8 pills × 147.7 mg/pill), which still represents a roughly 530% higher annual MDMA exposure for the imaging groups according to their calculations. The extracted text does not clearly report the sample sizes or dose summaries for each individual imaging study in the body text, but summary tables and supplementary material were cited as sources of the numerical details.

Szigeti and colleagues conclude that SERT neuroimaging studies have tended to recruit unusually heavy ecstasy users relative to the broader population of recent ecstasy pill users captured in the GDS. Because SERT reductions reported in the imaging literature show a dose‑response relationship with MDMA exposure, the authors infer that the extent of serotonergic alterations reported in the literature may overestimate the effects experienced by the majority of recreational users, who typically use less frequently and ingest fewer pills per year. They further note that among the small number of imaging subgroups whose Dose Intensity was similar to or below the GDS mean, SERT binding did not differ from matched controls, which is consistent with the possibility that low to moderate real‑world use produces minimal long‑term SERT changes. The discussion also highlights alternative interpretations and uncertainties: decreases in PET SERT binding may reflect adaptive internalisation of SERT rather than irreversible neuronal loss, because in vitro work suggests common PET tracers such as 11C‑DASB bind less to internalised than to membrane‑bound functional SERT. Polydrug use, environmental factors such as ambient temperature, and other moderators identified in animal and human studies complicate causal interpretation of SERT differences. The authors acknowledge several limitations of their analysis. GDS is a non‑random, self‑selected survey and may over‑represent people with greater interest in drugs, so it cannot be assumed fully representative of all ecstasy users. Self‑report bias and the absence of forensic confirmation that GDS participants’ pills contained MDMA are further constraints. The primary exposure metric was number of pills used, which is an imperfect proxy for true MDMA exposure; although pill‑testing data were used to partially address this, retrospective reconstruction of exact MDMA exposure is impossible. Additionally, GDS did not record Lifetime Exposure or Time of Use in a manner directly comparable with the imaging studies, and median dosing was rarely reported for imaging participants. In terms of implications, the authors recommend that future neuroimaging research include ecstasy/MDMA users more representative of the real‑world population, or that controlled clinical studies with limited administrations (for example, MDMA‑assisted psychotherapy protocols that typically administer about 125 mg with an optional 62.5 mg supplemental dose across 2–4 sessions) continue to monitor serotonergic markers, since such therapeutic exposure levels are considerably lower than the average reported in the GDS. Finally, the authors express the hope that their analysis will inform reinterpretation of the extant imaging literature and contribute to reconsideration of MDMA as a therapeutic tool.